Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_4

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

2(40.0%)

Phase 4Post-market surveillance

3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (40.0%)

Phase 43 (60.0%)

Trials by Status

terminated120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919

completedphase_2

Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?

NCT00846859

Clinical Trials (5)

Showing 5 of 5 trials

NCT04167306Phase 2

Varenicline and Bupropion for Alcohol Use Disorder

Completed

NCT02575183Phase 4

Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation

Completed

NCT02473562Phase 4

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

Terminated

NCT00802919Phase 4

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

Completed

NCT00846859Phase 2

Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?

Completed

All 5 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 5